Kristeen Maniscalco - Concepedia

Author

Kristeen Maniscalco

GlaxoSmithKline (United States)

Also Known As

K MANISCALCO, Kristeen Maniscalco

Publications

401

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)GlaxoSmithKline (United Kingdom)

About

Kristeen Maniscalco is an author at GlaxoSmithKline (United States) specializing in physiology, medicine, and heart failure.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	308
2	Health Sciences	1	1	40
3	Biochemistry	1	1	59
4	Cell Biology	1	1	102
5	Cellular Physiology	1	1	102

Kristeen Maniscalco

Publications

400

Citations

H-Index

Page 1

	Year	Citations
Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators Douglas G. Johns, Zhaohui Ao, Diane P. Naselsky, Naunyn-Schmiedeberg s Archives of Pharmacology Cardiac MuscleCardiomyopathyHeart FailureMolecular PhysiologyMedicine	2004	102
Deletion of the UT receptor gene results in the selective loss of urotensin‐II contractile activity in aortae isolated from UT receptor knockout mice David J. Behm, Stephen Harrison, Zhaohui Ao, British Journal of Pharmacology HypertensionHeart FailureCardiovascular PharmacologyUrotensin‐ii Contractile ActivityCardiovascular Function	2003	65
Comparison of Soluble Guanylate Cyclase Stimulators and Activators in Models of Cardiovascular Disease Associated with Oxidative Stress Melissa H. Costell, Nicolas Ancellin, Roberta E. Bernard, Frontiers in Pharmacology HypertensionHeart FailureCardiovascular DiseaseBiochemistryNitric Oxide	2012	59
Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease Robert N. Willette, Marianne Eybye, Alan R. Olzinski, Journal of Pharmacology and Experimental Therapeutics	2009	50
Urotensin-II: a novel systemic hypertensive factor in the cat Kristeen Maniscalco, Gerald P. Stankus, Alexandra Wibberley, Naunyn-Schmiedeberg s Archives of Pharmacology HypertensionUrologyAntihypertensive TherapyPhysiologyMedicine	2004	42
Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection Alan R. Olzinski, T MCCAFFERTY, Shui‐Ping Zhao, Cardiovascular Research	2005	42
PPARδ Activation Normalizes Cardiac Substrate Metabolism and Reduces Right Ventricular Hypertrophy in Congestive Heart Failure Beat M. Jucker, Christopher Doe, Christine G. Schnackenberg, Journal of Cardiovascular Pharmacology Cardiac MuscleHeart FailureCardiovascular PharmacologyPharmacotherapyCardiovascular Function	2007	40

Page 1